The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias
Open accessAbstract
Peak-dose dyskinesias are abnormal movements that usually occur 1 h after oral administration of levodopa, and often complicate chronic treatment of Parkinson's disease. We investigated by PET with [11C]raclopride whether Parkinson's disease progression modifies the striatal changes in synaptic dopamine levels induced by levodopa administration, and whether this modification, if present, could have an impact on the emergence of dyskinesias. We found that, 1 h after oral administration of standard-release 250/25 mg of levodopa/carbidopa, levodopa-induced increases in synaptic dopamine levels (as estimated by striatal changes in [11C]raclopride binding potential) correlated positively with duration of Parkinson's disease symptoms (for the caudate nucleus, r = 0.79, P < 0.001; for the putamen, r = 0.88, P < 0.0001). Patients with peak-dose dyskinesias had larger 1-h increases in synaptic dopamine levels than stable responders, but there were no between-group differences in [11C]raclopride binding 4 h post-levodopa. The corresponding (time x group) interaction term in the repeated measures analysis of covariance was significant, even after adjusting for between-group differences in duration of Parkinson's disease symptoms (for the caudate nucleus, P = 0.030; for the putamen, P = 0.021). Our results indicate that, at the synaptic level, an identical dose of levodopa induces increasingly larger 1-h changes in dopamine levels as Parkinson's disease progresses. Large levodopa-induced increases in synaptic dopamine concentration can lead to dramatic changes in receptor occupancy, which may be responsible for the emergence of peak-dose dyskinesias in Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical Statistics for Medical Research.
Walter, S. D., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,668
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
Grace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease
de la Fuente-Fernández, R., Ruth, T. J., Sossi, V., Schulzer, M., Calne, D. B., & Stoessl, A. J. (2001) · Science · doi:10.1126/science.1060937 · Cited by 991
Self-citationCriteria for diagnosing Parkinson's disease
Calne, D. B., Snow, B. J., & Lee, C. (1992) · Annals of Neurology · doi:10.1002/ana.410320721 · Cited by 628
Analysis of Emission Tomographic Scan Data: Limitations Imposed by Resolution and Background
Kessler, R. M., Ellis, J. R., & Eden, M. (1984) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198406000-00028 · Cited by 430
Levodopa‐induced dyskinesia: Review, observations, and speculations
Nutt, M. (1990) · Neurology · doi:10.1212/wnl.40.2.340 · Cited by 358
The Structural Organization of the Readily Releasable Pool of Synaptic Vesicles
Rizzoli, S. O., & Betz, W. J. (2004) · Science · doi:10.1126/science.1094682 · Cited by 337
Cited by
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
Self-citationOlanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 547
Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.554 · Cited by 497
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N., & Picconi, B. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70218-0 · Cited by 388
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
Kish, S. J., Tong, J., Hornykiewicz, O., Rajput, A., Chang, L.-J., Guttman, M., & Furukawa, Y. (2007) · Brain · doi:10.1093/brain/awm239 · Cited by 375
Stocchi, F., Rascol, O., Kieburtz, K., Poewe, W., Jankovic, J., Tolosa, E., Barone, P., Lang, A. E., & Olanow, C. W. (2010) · Annals of Neurology · doi:10.1002/ana.22060 · Cited by 374
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., & Lang, A. E. (2018) · Annals of Neurology · doi:10.1002/ana.25364 · Cited by 340
Cilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Voon, V., Fernagut, P.-O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos, J. L., Obeso, J. A., & Bezard, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70287-x · Cited by 335
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Fieblinger, T., Graves, S. M., Sebel, L. E., Alcacer, C., Plotkin, J. L., Gertler, T. S., Chan, C. S., Heiman, M., Greengard, P., Cenci, M. A., et al. (2014) · Nature Communications · doi:10.1038/ncomms6316 · Cited by 295
García-Borreguero, D., Allen, R. P., Kohnen, R., Högl, B., Trenkwalder, C., Oertel, W., Hening, W. A., Paulus, W., Rye, D., Walters, A., et al. (2007) · Sleep Medicine · doi:10.1016/j.sleep.2007.03.022 · Cited by 285
Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia
Cenci, M. A. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.005 · Cited by 265
Lindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., & Cenci, M. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06556.x · Cited by 263
Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia
Rylander, D., Parent, M., O'Sullivan, S. S., Dovero, S., Lees, A. J., Bezard, E., Descarries, L., & Cenci, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.22097 · Cited by 262
Blesa, J., Trigo-Damas, I., Dileone, M., del Rey, N. L.-G., Hernandez, L. F., & Obeso, J. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.002 · Cited by 256
Norepinephrine: The redheaded stepchild of Parkinson's disease
Rommelfanger, K. S., & Weinshenker, D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.036 · Cited by 255
Serotonin–dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias
CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00922-9 · Cited by 131
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features
Ray Chaudhuri, K., Poewe, W., & Brooks, D. (2018) · Movement Disorders · doi:10.1002/mds.27386 · Cited by 121
Willeit, M., Ginovart, N., Graff, A., Rusjan, P., Vitcu, I., Houle, S., Seeman, P., Wilson, A. A., & Kapur, S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301400 · Cited by 107
“…behavioral (Koepp et al, 1998; de la FuenteFernandez et al, 2002; Pruessner et al, 2004; Zald et al, 2004; Volkow et al, 2006) and pharmacological manipulations (Farde et al, 1992; Volkow et al, 1994; Tedroff et al, 1996; de la Fuente-Fernandez et al, 2004), which raise endogenous dopamine levels.”
BackgroundThe dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers.
Liggins, J., Pihl, R. O., Benkelfat, C., & Leyton, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028370 · Cited by 58
Thomsen, M., Stoica, A., Christensen, K. V., Fryland, T., Mikkelsen, J. D., & Hansen, J. B. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114209 · Cited by 8
Metadata
- Authors
- de la Fuente-Fernandez, R.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-11-10
- Volume
- 127
- Issue
- 12
- Pages
- 2747-2754
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2106158259
- Cited by
- 402
- References
- 26
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.